Abstract
We recently discovered a putative paclitaxel response predictive biomarker for glioblastoma and breast cancer using the whole genome CRISPR knockout screen. The biomarker candidate was validated in two independent breast cancer patient cohorts that received taxane treatment. To further evaluate the potential application of this biomarker in the clinic for patients with glioblastoma, a prospective validation in cohorts of patients with glioblastoma is essential and will be performed as part of our ongoing phase II clinical trial (NCT04528680). The validation of novel biomarkers of susceptibility to therapy is critical to elucidate the efficacy signal of therapeutic agents. This is especially important in the context of glioblastoma, where therapeutic benefit is variable and unpredictable, leading to negative trials, yet the outcome of subset of patients has outperformed expectations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 117-122 |
| Number of pages | 6 |
| Journal | Oncotarget |
| Volume | 15 |
| DOIs | |
| State | Published - 2024 |
Funding
The images in Figure 1 were created with https://www.biorender.com/. This work was supported by 1R01CA245969-01A1 (A.M.S), funding support from the Lou and Jean Malnati Brain Tumor Institute (A.M.S), philanthropic support from Dan and Sharon Moceri Foundation (A.M.S.). This work was supported by Northwestern Brain Tumor SPORE Career Enhancement Program (P50CA221747) to C.D.
Keywords
- CRISPR screen
- glioblastoma
- paclitaxel
- predictive biomarker
ASJC Scopus subject areas
- Oncology
